Takeda Pharmaceutical Company Limited

Boehringer Ingelheim International Gmbh

Dyax Corporation

Stephen R Comeau

Andrew Nixon

Jon A Kenniston

Burt Adelman

Shauna Mason

Daniel J Sexton

Gregory P Conley

Allison P Lindberg

Niksa Kastrapeli

Kristopher Kopacz

Klaus-Peter Kuenkele

Pankaj Gupta

Paul Adam

Karl-Heinz Heider

Elinborg Ostermann

Priyanka Gupta

Philip Nicholas Gorman

Renate Konopitzky

Sandeep Kumar

Andreas Wernitznig

Abdulsalam Shaaban

Srinath Kasturirangan

David Weismann

David S Young

Taneisha Ann-Tanara Mack

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

Monoclonal antibody inhibitor of Factor XIIa

The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Tri-specific binding molecules

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.

Bispecific antibodies against plasma kallikrein and factor XII

Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

Anti-plasma kallikrein antibodies

Bispecific antibodies against plasma kallikrein and Factor XII

Monoclonal antibody inhibitor of factor XIIA

Growing community of inventors

Avon, NY, United States of America

Stephen R Comeau